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ABSTRACT
Objective: In patients with acute ischemic stroke, we aimed to investigate the relation between
preexisting small vessel disease (SVD) and the amount of blood–brain barrier (BBB) leakage in
ischemic and nonischemic area before IV thrombolysis.
Methods: We retrospectively accessed anonymous patient-level data from the Stroke Imaging
Repository and the Virtual International Stroke Trials Archive resources and included patients
treated with IV thrombolysis with pretreatment MRI. We rated SVD features using validated qual-
itative magnetic resonance (MR) scales. Leakage of BBB was assessed with postprocessing of
perfusion-weighted images. We evaluated associations between SVD features (individually and
summed in a global SVD score) and BBB leakage using linear regression analysis, adjusting for
major clinical confounders.
Results: A total of 212 patients, mean age (6SD) 69.5 years (616.1), 102 (48%) male, had
available MR before IV thrombolysis. Evidence of BBB leakage was present in 175 (80%) and
205 (94%) patients in the ischemic and nonischemic area, respectively. Lacunar infarcts (b 5
0.17, p 5 0.042) were associated with BBB leakage in the ischemic area, and brain atrophy was
associated with BBB leakage in both ischemic (b 5 0.20, p 5 0.026) and nonischemic (b 5 0.27,
p5 0.001) areas. Increasing SVD grade was independently associated with BBB leakage in both
ischemic (b 5 0.26, p 5 0.007) and nonischemic (b 5 0.27, p 5 0.003) area.
Conclusions: Global SVD burden is associated with increased BBB leakage in both acutely ische-
mic and nonischemic area. Our results support that SVD score has construct validity, and confirm
a relation between SVD and BBB disruption also in patients with acute stroke. Neurology®
2017;89:2143–2150
GLOSSARY
ANOVA 5 analysis of variance; BBB 5 blood–brain barrier; FLAIR 5 fluid-attenuated inversion recovery; MPD 5 mean
permeability derangement; MR 5 magnetic resonance; NIHSS 5 NIH Stroke Scale; OTT 5 onset-to-treatment time; ROI 5
region of interest; rtPA 5 recombinant tissue plasminogen activator; SVD 5 small vessel disease; TTP 5 time-to-peak;
VSS 5 Van Swieten Scale.
Small vessel disease (SVD) refers to a wide range of pathologic processes that affect microcircu-
lation in the brain.1 Effects of SVD on brain parenchyma can be detected in vivo with either CT
or magnetic resonance (MR) scan. Imaging phenotypes of SVD include white matter changes,
lacunar strokes, cerebral microbleeds, enlarged perivascular spaces, and brain atrophy.2 More-
over, postmortem studies have identified microscopic pathologic features, such as cortical micro-
infarcts and changes in the normal-appearing white matter, which are undetectable with
conventional imaging, suggesting that the SVD seen on imaging studies is only part of a larger
spectrum.3 Recently, the concept that a global estimate of SVDmay provide a better overview of
the effect of the pathology on the brain than one single SVD feature resulted in the development
of a combined score,4 which has been validated in regards to cognitive status.5
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SVD has been associated with dysfunction of
the blood–brain barrier (BBB).6 Animal models
using chronic cerebral hypoperfusion to produce
SVD7 have identified deficits of BBB integrity,
and it has been suggested that SVD may lead to
BBB damage through endothelial dysfunction8
and subsequent inflammatory process.9 Con-
versely, some authors have hypothesized that
BBB disruption itself may play a pathogenic role
in SVD. In fact, BBB leakage is present in
normal-appearing white matter in patients with
leukoaraiosis,10 and areas of normal-appearing
white matter with BBB leakage seems to predate
development of white matter changes.11 How-
ever, SVD is a composite product of various
imaging features, and it is not known whether
combining different rather than single SVD fea-
tures could provide information on the amount
of BBB disruption. In this cross-sectional study
of patients with acute ischemic stroke suitable
for treatment with recombinant tissue plasmin-
ogen activator (rtPA), we sought to investigate
the associations between increasing grade of
individual and summed imaging markers con-
sistent with SVD and levels of BBB leakage
within the following:
1. The acutely ischemic region
2. The regions remote from acute ischemia
METHODS Patients. We accessed patient-level data from the
Stroke Imaging Repository/Virtual International Stroke Trials
Archive resource to perform a retrospective analysis. We included
patients with acute ischemic stroke with available MRI before IV
thrombolytic treatment with rtPA. All patients included in the
present study received rtPA after MR scanning.
Clinical variables of interest included age, sex, and baseline
(before rtPA treatment) variables, such as stroke severity assessed
with NIH Stroke Scale (NIHSS), blood glucose, blood pressure,
and time from stroke symptoms onset to rtPA administration
(onset-to-treatment time [OTT]), as a surrogate of time from
symptom onset to brain imaging. We included anamnestic rele-
vant cardiovascular risk factors such as hypertension, diabetes,
atrial fibrillation, hypercholesterolemia, and history of smoking
(current and past).
SVD assessment. A stroke neurologist (F.A.) trained in MR
assessment for SVD and blinded to clinical and BBB leakage data
rated all the available scans (T1, T2, fluid-attenuated inversion
recovery [FLAIR] sequences) for presence and severity of SVD
features, according to Standards For Reporting Vascular Changes
on Neuroimaging recommendations.2 An expert stroke physician
(D.I.) cross-checked the ratings. Although previous attempts of
SVD score also included microbleeds and enlarged perivascular
spaces,4 to allow transferability of methods to CT, we only con-
sidered MR surrogates of SVD detectable with CT scan. We
therefore rated preexisting lacunes, white matter hyperintensities,
and brain atrophy. We defined lacunes as round CSF isointense
lesions measuring #20 mm in diameter on axial section in the
white matter, basal ganglia, or brainstem on T1, T2, or FLAIR
sequences. We graded white matter hyperintensities as 0–2 ac-
cording to the Van Swieten Scale (VSS) in anterior and posterior
periventricular white matter to obtain a 5-point ordinal scale
(0–4).12 Brain atrophy was defined as deep and cortical, and rated
as none, mild-moderate and severe against a reference MR brain
template, then we combined the deep and cortical scores into a 5
point ordinal scale (0–4).13
For assessment of total SVD burden, we built a combined
aggregate SVD score as follows: we summed the scores of white
matter changes, lacunes, and brain atrophy, assigning 1 point
for each of the following: severe white matter changes (VSS
$ 3), lacunes ($2), and severe brain atrophy ($3). The resulting
4-point ordinal score evaluated the global burden of SVD from
0 (no imaging features of severe SVD) to 3 (imaging features of
SVD scored as severe for each imaging variable). The aforemen-
tioned SVD score has been previously evaluated on clinical out-
comes14 and white matter perfusion.15
BBB leakage assessment. BBB leakage was calculated by one
author (R.L.) blinded to demographic and clinical data. The anal-
ysis was performed on the dynamic susceptibility contrast source
images that are acquired in stroke patients for the purpose of gen-
erating perfusion-weighted images. We obtained a relative mea-
sure of BBB leakage comparing the signal change in regions of
intact BBB with the signal change in regions with BBB disrup-
tion. Normal tissue was identified using an automated process
that excludes regions of BBB disruption based on signal charac-
teristics. We separately assessed BBB leakage in regions of hy-
poperfusion, representing the ischemic brain area, and regions
with normal perfusion, representing the background brain status.
Selection of the gadolinium injection time was done by visual
inspection. All other aspects of the analysis were automated (see
e-Methods at Neurology.org).
BBB disruption calculations were performed in these 2 re-
gions of interest (ROIs) that were defined by time-to-peak
(TTP) maps. The acute ROI, identifying the ischemic area in
the affected hemisphere, was defined by region with a TTP delay
of greater than 4 seconds, with all other regions falling into the
nonacutely ischemic ROI. Although cerebral blood flow is differ-
ent in gray vs white matter, TTP maps are relatively insensitive to
these differences, and thus, when using a threshold of 4 seconds,
the resulting ROI represents acute perfusion deficit of the
involved vascular territory (figure 1). Thus the region remote
from the acute ischemia comprises the rest of the brain (outside
of the TTP lesion). We defined mean permeability derangement
(MPD) as the mean value of all the voxels greater than the
derangement threshold within the ROI. MPD is used to identify
regions of focal high BBB derangement (figure 1). The BBB
quantification was performed with an automated script in MAT-
LAB software package, thus there was no user dependence or
variability between repeated calculations. All BBB leakage calcu-
lations were submitted prior to unblinding.
Standard protocol approvals, registrations, and patient
consents. Ethical approval was not required as the dataset was
anonymized. The NIH Office of Human Subjects Research
Protections determined that the BBB analysis, which was con-
ducted at the NIH, did not require institutional review board
approval.
Statistical analysis. We described general characteristics of the
population with summary statistics, and used analysis of variance
(ANOVA), Kruskal-Wallis, and Pearson x2, as appropriate, to test
differences among groups. For the purposes of the present study,
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we performed a normal logarithmic transformation of BBB
leakage values to obtain normally distributed data. We
therefore evaluated associations between single SVD features,
SVD score, and BBB leakage with ANOVA. To investigate
independent associations, we built multivariable linear
regression models with SVD features and SVD score as
explanatory variables and BBB leakage as dependent variable.
For BBB leakage within the ischemic area, we adjusted the
analysis for relevant confounders in acute stroke physiopa-
thology, such as age, sex, stroke severity, baseline glucose, and
OTT. For BBB leakage in the nonischemic area, we adjusted
the analysis for relevant confounders in SVD such as age, sex,
hypertension, diabetes, and smoke exposure. In a further
multivariable model, we adjusted the analysis for all the
aforementioned variables in the same analysis. We considered
a p value,0.05 statistically significant. Statistical analysis was
carried out using SPSS for Windows (version 22.0; SPSS, IBM
Corp., Armonk, NY).
RESULTS From a database of 285 patients, 219
(77%) had both clinical data and baseline MR scans
of interest for the purposes of the present study. In
7 patients, MR assessment was not possible for tech-
nical reasons (poor scan quality or incomplete se-
quences). This left 212 (74% of the original
dataset) patients with pretreatment MR scans avail-
able for the analysis.
Demographic and clinical characteristics of pa-
tients included in the study are listed in table 1. Mean
age (6SD) was 69.5 6 16.1 years; 102 (45%) pa-
tients were male. Median baseline NIHSS was 10;
75% of patients had a NIHSS .5; hypertension
was the most frequent risk factor (71%).
Distribution of single SVD features is shown in
figure e-1. Seventy-eight (37%) patients had evidence
of severe white matter changes, 42 (20%) had 2 or
more lacunes, 86 (41%) had brain atrophy graded
as severe. The combined SVD score showed 95
(45%) patients with absence of SVD signs (score
0), 48 (23%) patients with mild SVD (score 1), 49
(23%) patients with moderate SVD (score 2), and
20 (9%) patients with severe SVD (score 3) burden.
As expected, hypertension (p 5 0.001) and atrial
fibrillation (p 5 0.002) prevalence increased with
SVD burden.
Acute ischemic region and BBB leakage. Before IV rtPA
administration, 175 (80%) patients showed some
degree of BBB leakage within the ischemic area, with
a mean (6SD) derangement of 3.02 (60.59). Uni-
variate analysis showed that permeability increased
with severity of white matter changes (p 5 0.006),
Figure 1 An example of blood–brain barrier (BBB) leakage detected with MRI
(A) Source image from the dynamic susceptibility contrast scan with the acute ischemic region of interest (ROI) shaded in
blue. (B) BBB leakage map within the acute ROI. Regions of BBB leakage are overlain on the dynamic susceptibility contrast
source image according to the color code in the legend with red representing the most severe areas of BBB disruption. (C)
Corresponding diffusion-weighted image (DWI), which was not used in the analysis but is shown to demonstrate the pattern
of elevated (red) BBB leakage in the region that is bright (acutely ischemic) on the DWI. (D) BBB leakage map for regions
remote from the acute ischemia. (E) The corresponding fluid-attenuated inversion recovery (FLAIR) image and small vessel
disease (SVD). The SVD composite score for this patient is 3. Note the pattern of increased BBB leakage at the junction
between the white matter hyperintensities and the normal-appearing white matter. (F) FLAIR image from a follow-up
MRI in which the previously administered gadolinium has leaked through the BBB into the CSF, causing a lack of CSF
suppression.
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grade of brain atrophy (p 5 0.005), and number of
lacunes (p5 0.008) (figure e-2). The combined SVD
score was strongly associated with BBB leakage (mean
permeability 2.84 for SVD 5 0; 3.00 for SVD 5 1;
3.21 for SVD 5 2; 3.39 for SVD 5 3; p , 0.001;
figure 2). Multivariable linear regression analysis
among single SVD features showed that severe brain
atrophy (b 5 0.20; p 5 0.026) and preexisting lacu-
nar infarcts (per lacunar infarct increase, b 5 0.17;
p 5 0.042) were associated with BBB leakage,
whereas both brain atrophy (as ordinal scale) and
white matter changes were not. Compared to single
SVD features and to its single components, the com-
bined SVD score displayed a stronger association with
BBB leakage (b 5 0.26; p 5 0.007, b 5 0.25; p 5
0.014 in 2 multivariable models; table 2).
Regions remote to the acute ischemia and BBB
derangement. At baseline, 202 (95%) patients had evi-
dence of BBB leakage in regions remote from the
acute ischemia, with a mean (6SD) derangement of
2.87 (60.64). Similarly to the analysis in the acute
ischemic region, univariate analysis showed that BBB
leakage increased with grade of white matter changes
(p 5 0.019) and brain atrophy (p , 0.001), whereas
number of lacunes were not associated with BBB
leakage (figure e-3). The combined SVD score was
associated with increased BBB leakage (mean perme-
ability 2.67 for SVD5 0; 2.97 for SVD5 1; 2.99 for
SVD 5 2; 3.33 for SVD 5 3; p , 0.001; figure 3).
Multivariate linear regression showed that brain atro-
phy was independently associated with BBB leakage
(b5 0.25; p5 0.006), whereas white matter changes
and lacunes were not. However, the combined SVD
score confirmed the association with BBB leakage in
the 2 multivariable models (b 5 0.27; p 5 0.003,
b 5 0.22; p 5 0.013; table 2).
DISCUSSION We investigated BBB leakage before
IV rtPA in a population of ischemic stroke patients.
We found that BBB leakage in regions remote
from the acute lesion occurred more frequently than
BBB leakage in acute ischemic regions, even though
Table 1 Baseline characteristics of study patients
Total population (n 5 212) SVD 0 (n 5 95) SVD 1 (n 5 48) SVD 2 (n 5 49) SVD 3 (n 5 20) p
Age, y 69.5 6 16.1 59.9 6 16.0 73.3 6 12.4 80.9 6 7.9 80.3 6 7.3 ,0.001
Sex, male 102 (45) 49 (52) 23 (48) 21 (43) 9 (45) 0.782
Weight, kg 78.8 6 17.7 83.4 6 17.6 78.2 6 19.9 70.3 6 12.7 74.6 6 14.5 0.028
Hypertension 150 (71) 54 (57) 42 (88) 38 (78) 16 (80) 0.001
Diabetes 47 (22) 19 (20) 13 (27) 7 (14) 8 (40) 0.094
Hyperlipidemia 98 (46) 42 (44) 29 (60) 19 (39) 8 (40) 0.142
Atrial fibrillation 59 (28) 14 (15) 18 (38) 18 (37) 9 (45) 0.002
Smoking 57 (27) 25 (26) 10 (21) 15 (31) 7 (35) 0.588
Baseline NIHSS 10 (5–17) 8 (4–12) 10 (7–19) 13 (6–20) 11 (6–14) 0.019
OTT, min 165 (138–180) 157 (130–180) 170 (143–179) 161 (131180) 177 (165218) 0.051
Systolic BP, mm Hg 152.4 6 25.8 149.8 6 22.5 152.9 6 28.8 160.4 6 30.6 152.3 6 25.7 0.450
Diastolic BP, mm Hg 79.9 6 22.5 79.9 6 13.2 86.0 6 17.6 87.2 6 14.6 81.4 6 15.2 0.112
Glucose, mg/dL 133.3 6 57.1 133.3 6 57.1 129.3 6 42.1 129.1 6 41.7 158.8 6 90.7 0.899
Ischemic region BBB leakage 3.02 6 0.59 2.84 6 0.57 3.00 6 0.56 3.21 6 0.49 3.39 6 0.63 ,0.001
Nonischemic region BBB leakage 2.87 6 0.64 2.67 6 0.65 2.97 6 0.59 2.99 6 0.57 3.33 6 0.55 ,0.001
Abbreviations: BBB 5 blood–brain barrier; BP 5 blood pressure; NIHSS 5 NIH Stroke Scale; OTT 5 onset-to-treatment time; SVD 5 small vessel disease.
Data are n (%), mean 6 SD, or median (interquartile range).
Figure 2 Blood–brain barrier leakage (mean and 95% confidence interval [CI])
within the ischemic area across small vessel disease (SVD) score
ANOVA 5 analysis of variance.
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the latter had higher values than the former. Brain
atrophy and lacunes were associated with increased
BBB leakage; however, a summed SVD score was
more strongly associated with increasing BBB leakage
throughout the brain, suggesting that the use of
a combined score accounting for the global SVD bur-
den may provide more complete information with re-
gard to BBB leakage.
Consistently with prior reports,16–19 we found
that some degree of BBB leakage was a common
event in acute stroke patients. Remarkably, almost
all patients (95%) had some amount of BBB leak-
age remotely from the acute ischemia compared
with 80% in regions with acute ischemia. Although
increasing amount of BBB derangement is likely
pathologic, small amount of BBB leakage could
be not related with disease, and this may explain
the high frequency of patients with evidence of
BBB disruption. Furthermore, BBB derangement
increases with normal aging and in patients with
SVD,17 and is thought to be one of the key patho-
logic changes of SVD.4,11,17 A recent consensus
statement pointed out that increased BBB perme-
ability may trigger SVD pathology,20 and our find-
ings seems to corroborate this hypothesis, showing
almost all patients with BBB leakage despite
around half of our population with imaging signs
of SVD.
SVD has a various imaging phenotype and we
found that single features of SVD had a substan-
tially different contribution to BBB leakage
between chronic and acute damage. Conversely to
a previous study,10 we did not found any associa-
tion between white matter changes and BBB leak-
age. However, this may support the hypothesis that
BBB disruption precedes the development of white
matter disease rather than being primarily associ-
ated with established white matter changes.11,20
Brain atrophy was strongly associated with BBB
leakage. This finding is in keeping with a systematic
review and meta-analysis, which showed a more
pronounced BBB leakage in patients with vascular
dementia compared to Alzheimer disease or con-
trols.21 Similarly to previous studies,6,18 we found
that lacunes were associated with an increase of
BBB leakage, although the association was inde-
pendent only within the ischemic area. More
importantly, we showed that a combined score
accounting for the global SVD burden performed
better than single SVD score components with
Figure 3 Blood–brain barrier leakage (mean and 95% confidence interval [CI])
within the nonischemic area across small vessel disease (SVD) score
ANOVA 5 analysis of variance.
Table 2 Linear regression analysis with blood–brain barrier (BBB) leakage as dependent variable
BBB leakage in the ischemic area
BBB leakage in the nonischemic
area
b SE p b SE p
Brain atrophy (per point increase) 0.19 0.05 0.064 0.25 0.04 0.007
Severe brain atrophy 0.20 0.11 0.026 0.27 0.10 0.001
White matter changes (per point increase) 0.21 0.05 0.053 0.14 0.05 0.135
Severe white matter changes 0.17 0.12 0.087 0.12 0.11 0.149
Lacunes (per lacune increase) 0.17 0.04 0.042 0.07 0.04 0.347
Two or more lacunes 0.12 0.13 0.136 0.09 2.65 0.203
SVD score (per point increase)a 0.26 0.06 0.007 0.27 0.05 0.003
SVD score (per point increase)b 0.25 0.06 0.014 0.22 0.05 0.013
Abbreviations: NIHSS 5 NIH Stroke Scale; SVD 5 small vessel disease.
aAnalysis for BBB leakage in the ischemic area adjusted for age, sex, onset-to-treatment time, baseline glucose, and
baseline NIHSS; for BBB leakage in nonischemic area, adjusted for age, sex, hypertension, diabetes, and smoking exposure.
bAnalysis adjusted for age, sex, onset-to-treatment time, baseline glucose, baseline NIHSS, hypertension, diabetes, and
smoking exposure.
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regards to BBB disruption. The independent asso-
ciations of the SVD score with increased BBB leak-
age in both hemispheres suggested that a combined
score may reliably act as a useful surrogate marker
of SVD and convey an good overall view of the
pathology and its grade and effect on the brain.
Although we conducted a cross-sectional study
and cannot draw any conclusion about causal rela-
tionship, we found a linear relation between
increasing SVD burden and BBB leakage, alluding
to a dose-response effect between the 2 features,
thus reinforcing the association. Future larger stud-
ies may assess validity of our methodology of BBB
disruption and SVD and explore their long-term
relation.
We found a more pronounced increase of BBB
leakage in the ischemic area compared to the area
remote to brain ischemia before rtPA treatment.
Evidence suggests that rtPA boosts BBB permeabil-
ity within the ischemic area in acute stroke patients
treated with IV thrombolysis with successful recan-
alization, and may therefore contribute to the so-
called reperfusion injury.19,22,23 As a consequence,
BBB disruption within the ischemic area after rtPA
treatment has been proposed as an intermediate
marker of patients at risk to develop hemor-
rhage.24,25 However, our results showed that vari-
ous degree of BBB leakage is present also before
rtPA administration, and therefore independent
from either rtPA itself or recanalization process.
This is in keeping with a recent study that showed
that a mild BBB leakage before thrombolytic treat-
ment is reversible after reperfusion, while severe
BBB leakage is associated with irreversible BBB
rupture and subsequent increasing risk of post-
thrombolysis intracranial hemorrhage.26 We dem-
onstrated that preexisting characteristics of the
brain, such as presence and grade of SVD, might
modulate the amount of BBB permeability in the
acutely ischemic area. Complex interactions among
endothelial dysfunction,8 inflammation,16 and the
integrity of the neurovascular unit27 might contrib-
ute to the worsening of BBB function in patients
with SVD. This may be clinically relevant for 2
main reasons. First, SVD is frequent in patients
with acute ischemic stroke (we found around
one-third of the study population with moderate
to severe global burden of SVD), and second, BBB
leakage has been associated with hemorrhagic
transformation after acute stroke treatment. Future
studies might investigate whether SVD and BBB
disruption interact with hemorrhagic transforma-
tion or worse outcomes after rtPA and endovascular
procedures.
Strengths of our study are the large sample size,
the standardized assessment of SVD with largely
validated scales, and the blinded evaluation of both
SVD and BBB leakage. However, we acknowledge
several limits to our study. The analysis was per-
formed on a de-identified dataset obtained from
a public repository, thus the authors were not able
to confirm the protocol used to enroll each patient.
As a consequence, some selection bias interfering
with the data is plausible. However, all the
included patients were treated with IV rtPA after
MRI, and experts should have excluded potential
sources of bias (e.g., stroke mimics). The method-
ology we implemented for measuring BBB leakage
utilized an MR sequence that can be routinely
acquired as part of the evaluation of acute stroke
patients within the time frame of recognized guide-
lines.28 Although our permeability method is lim-
ited to reflect a relative rather than an absolute
measurement of the transfer constant, this has the
advantage that the measurement is normalized to
the scan it is obtained from, minimizing the effect
of scanner variability. Despite this advantage, it is
important to point out that the scan measures in
this study varied substantially in acquisition param-
eters and strength of the magnet and the scanner
manufacturers. This variability undoubtedly added
noise to the dataset and may have obscured impor-
tant associations other than those identified.
Although the methodology used in this study is
relatively new, it has been validated in different
datasets in patients with stroke29,30 and brain tu-
mors.31 Again, we acknowledge that the SVD score
we used needs validation and appropriate statistical
modeling for implementation in clinical practice.
However, we provided a proof-of-concept for the
SVD score as a tool for quantification of global
cerebral SVD. The same score previously proved
validity from 2 different datasets in relation to clin-
ical outcomes after acute stroke14 and white matter
perfusion.15 Finally, we did not have any informa-
tion about pathogenic mechanism of the index
strokes and we did not retain data on ischemic
lesion characteristics (e.g., size, location). How-
ever, the aim of the study was to give a picture of
the link between SVD and BBB immediately before
rtPA treatment in the acute scenario, irrespectively
from stroke pathogenesis. Whether stroke subtype
may influence BBB could be investigated in future
studies.
This study expands our knowledge about the
relationship between SVD and BBB in acute ische-
mic stroke, showing that BBB leakage is frequent
before rtPA treatment and that increasing SVD
burden is consistently associated with higher BBB
leakage also in the acutely ischemic area. Our re-
sults suggest that SVD and BBB leakage are inter-
related processes in both acutely ischemic and
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nonischemic area. Further studies to investigate
how SVD and BBB disruption interact with acute
stroke therapy are warranted.
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